

Matthew P Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10393406/publications.pdf>

Version: 2024-02-01

28
papers

3,544
citations

430754

18
h-index

610775

24
g-index

36
all docs

36
docs citations

36
times ranked

8487
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 517-525.	13.9	1,081
2	Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2. <i>Annals of Internal Medicine</i> , 2020, 172, 726-734.	2.0	517
3	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 623-631.	2.0	444
4	Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. <i>Nature Medicine</i> , 2021, 27, 1071-1078.	15.2	206
5	Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0252617.	1.1	185
6	SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e75-e76.	4.6	175
7	Blood Culture Results Before and After Antimicrobial Administration in Patients With Severe Manifestations of Sepsis. <i>Annals of Internal Medicine</i> , 2019, 171, 547.	2.0	125
8	Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2. <i>Annals of Internal Medicine</i> , 2020, 173, 450-460.	2.0	124
9	Prognostic factors in 264 adults with invasive <i>Scenedosporium</i> spp. and <i>Lomentospora prolificans</i> infection reported in the literature and FungiScope [®] . <i>Critical Reviews in Microbiology</i> , 2019, 45, 1-21.	2.7	106
10	Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 2159-2175.	2.5	89
11	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1037-1042.	0.5	83
12	Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw838.	2.9	73
13	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa500.	0.4	38
14	Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. <i>Cmaj</i> , 2020, 192, E405-E407.	0.9	36
15	Adjunctive Daptomycin in the Treatment of Methicillin-susceptible <i>Staphylococcus aureus</i> Bacteremia: A Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e196-e203.	2.9	34
16	Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab220.	0.4	33
17	Invasive <i>Scenedosporium</i> spp. and <i>Lomentospora prolificans</i> infections in pediatric patients: Analysis of 55 cases from FungiScope [®] and the literature. <i>International Journal of Infectious Diseases</i> , 2020, 92, 114-122.	1.5	23
18	Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 69, 869-872.	2.9	22

#	ARTICLE	IF	CITATIONS
19	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2020, 67, 1201-1211.	0.7	19
20	Neither Blood Culture Positivity nor Time to Positivity Is Associated With Mortality Among Patients Presenting With Severe Manifestations of Sepsis: The FABLED Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab321.	0.4	9
21	SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study. <i>Cmaj</i> , 2021, 193, E1868-E1877.	0.9	9
22	Cytomegalovirus events in high-risk allogeneic hematopoietic cell transplantation patients who received letermovir prophylaxis. <i>Transplant Infectious Disease</i> , 2021, 23, e13619.	0.7	8
23	Specificity of SARS-CoV-2 Antibody Detection Assays against S and N Proteins among Pre-COVID-19 Sera from Patients with Protozoan and Helminth Parasitic Infections. <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0171721.	1.8	7
24	Real-world Time to Positivity of 2 Widely Used Commercial Blood Culture Systems in Patients With Severe Manifestations of Sepsis: An Analysis of the FABLED Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa371.	0.4	5
25	Reply to Dobler. <i>Clinical Infectious Diseases</i> , 2017, 65, 1423-1424.	2.9	0
26	Authors'™ Response. <i>Journal of Thoracic Oncology</i> , 2018, 13, e237.	0.5	0
27	Reply to Aronson et al. <i>Clinical Infectious Diseases</i> , 2020, 70, 1262.	2.9	0
28	Optimizing cost as well as yield of blood cultures in sepsis. <i>American Journal of Emergency Medicine</i> , 2021, 47, 294.	0.7	0